Oncothyreon Inc. introduced its plan to provide, the subject of market as well as other conditions, posses of their common stock enduring an underwritten public providing. Oncothyreon also hopes to grant the financial advisors a 30-day choice to acquire up to one additional 15 percent of typical shares of typical stock available in the public offering to cover over-allotments, if any.
The goes on the providing would primarily be applied to fund the creation of PX-866, Oncothyreon's permanent pan-is form PI-3 kinase inhibitor, and ONT-10, Oncothyreon's valuable follow-on vaccine to Stimuvax. Stimuvax, currently in a Phase 3 crucial trial, is a vaccination for affected individuals with non-small cell lung cancer and it is incorporated Merck KGaA.
No comments:
Post a Comment